Bactrim Dose for PJP Prophylaxis
For adults, use one double-strength tablet (160/800 mg) daily or one double-strength tablet three times weekly on consecutive days; for children, use 150 mg/m² trimethoprim with 750 mg/m² sulfamethoxazole daily, divided into two doses and given three times weekly on consecutive days. 1
Adult Dosing
The FDA-approved prophylactic regimen is one double-strength tablet (TMP 160 mg/SMX 800 mg) daily 1. However, the three-times-weekly dosing on consecutive days is equally endorsed and widely used in clinical practice 2, 3.
Standard Regimens (in order of preference):
- 1 DS tablet daily - Most commonly prescribed
- 1 DS tablet three times weekly on consecutive days (e.g., Monday-Tuesday-Wednesday)
- 1 single-strength tablet (80/400 mg) daily - Alternative for tolerability
Recent evidence strongly supports that lower-dose regimens maintain efficacy while significantly reducing adverse events. Studies show no breakthrough PJP infections with doses as low as one single-strength tablet every other day, three times weekly 4, and twice-weekly dosing on non-consecutive days 5, 6.
Pediatric Dosing
For children ≥2 months: 150 mg/m² TMP with 750 mg/m² SMX per day, divided into two doses, given three times weekly on consecutive days (maximum 320 mg TMP/1600 mg SMX daily) 2, 1.
Practical pediatric dosing by body surface area:
- 0.26-0.53 m²: ½ tablet twice daily on prophylaxis days
- 0.53-1.06 m²: 1 tablet twice daily on prophylaxis days
Critical contraindication: Bactrim is absolutely contraindicated in infants <2 months of age 1.
Renal Dose Adjustment
For creatinine clearance 15-30 mL/min: reduce dose to 50% of standard regimen 1.
For creatinine clearance <15 mL/min: use is not recommended 1.
However, emerging evidence in hemodialysis patients suggests that very low doses (<6 single-strength tablets per week) maintain prophylactic efficacy with significantly fewer adverse events compared to standard dosing 7. For patients with even mild renal impairment (CrCl ≤64 mL/min or SCr ≥0.78 mg/dL), consider starting with reduced dosing as they have significantly higher discontinuation rates with standard doses 8.
Managing Intolerance
If patients cannot tolerate standard dosing due to adverse effects:
Step-down approach:
- First: Reduce to 1 single-strength tablet daily
- Second: Reduce to 1 single-strength tablet every other day, three times weekly
- Third: Reduce to 1 single-strength tablet twice weekly on non-consecutive days
Research demonstrates that even twice-weekly dosing on non-consecutive days prevents breakthrough PJP 5, 6, with one study showing 0% PJP incidence and significantly lower discontinuation rates (12.1% vs 35.6% yearly) compared to standard dosing 7.
Alternative agents if TMP-SMX must be discontinued:
- Dapsone: 100 mg daily (or 2 mg/kg in children)
- Atovaquone: 1500 mg daily (30-45 mg/kg in children depending on age)
- Aerosolized pentamidine: 300 mg monthly (children ≥5 years only) 2
Key Clinical Pearls
Daily TMP-SMX provides additional benefits beyond PJP prophylaxis, including reduction in bacterial respiratory infections and toxoplasmosis protection 3. This should be considered when selecting among dosing regimens.
Common pitfall: Prescribers often maintain high doses unnecessarily. The evidence strongly supports that lower doses (even twice weekly) maintain efficacy while dramatically reducing adverse events including hyperkalemia, neutropenia, thrombocytopenia, and hepatotoxicity 9, 8, 6.
For transplant recipients: Low-dose regimens (80/400 mg daily or 160/800 mg every other day) show equivalent efficacy to full-dose prophylaxis (0% vs 1% vs 11% PJP incidence for full-dose, low-dose, and no prophylaxis respectively) 10.
Monitoring: Watch for hyperkalemia (2.6% incidence), neutropenia (13.3%), thrombocytopenia (8.1%), elevated creatinine (15.9%), and transaminitis (5.9%) even with low-dose regimens 9.